NO20040101L - Hemming av apoptoseprosessen og forbedring av cellenes yteevne - Google Patents

Hemming av apoptoseprosessen og forbedring av cellenes yteevne

Info

Publication number
NO20040101L
NO20040101L NO20040101A NO20040101A NO20040101L NO 20040101 L NO20040101 L NO 20040101L NO 20040101 A NO20040101 A NO 20040101A NO 20040101 A NO20040101 A NO 20040101A NO 20040101 L NO20040101 L NO 20040101L
Authority
NO
Norway
Prior art keywords
cell
enhancement
inhibition
cell performance
production
Prior art date
Application number
NO20040101A
Other languages
English (en)
Norwegian (no)
Inventor
Mitchell E Reff
Michael J Betenbaugh
Jr Bruno Figueroa
Eric Ailor
Marie Hardwick
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of NO20040101L publication Critical patent/NO20040101L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
NO20040101A 2001-07-10 2004-01-09 Hemming av apoptoseprosessen og forbedring av cellenes yteevne NO20040101L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30381301P 2001-07-10 2001-07-10
PCT/US2002/021606 WO2003006607A2 (en) 2001-07-10 2002-07-10 Inhibition of apoptosis process and improvement of cell performance

Publications (1)

Publication Number Publication Date
NO20040101L true NO20040101L (no) 2004-03-09

Family

ID=23173824

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20040101A NO20040101L (no) 2001-07-10 2004-01-09 Hemming av apoptoseprosessen og forbedring av cellenes yteevne

Country Status (13)

Country Link
US (1) US7604989B2 (de)
EP (1) EP1414948B1 (de)
JP (2) JP4435563B2 (de)
KR (1) KR20040044433A (de)
CN (1) CN1526011A (de)
AT (1) ATE443131T1 (de)
AU (1) AU2002315534B2 (de)
CA (1) CA2452005C (de)
DE (1) DE60233738D1 (de)
MX (1) MXPA04000281A (de)
NO (1) NO20040101L (de)
WO (1) WO2003006607A2 (de)
ZA (2) ZA200508985B (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7812148B2 (en) 2001-04-05 2010-10-12 Millipore Corporation Vectors comprising CpG islands without position effect varigation and having increased expression
KR100454016B1 (ko) * 2002-01-05 2004-10-26 한국과학기술원 항예정사 유전자로 형질전환되고 ｄｈｆｒ 유전자가결핍된 신규한 ｃｈｏ 세포주, 그의 제조 방법 및 상기형질전환된 ｃｈｏ 숙주 세포를 이용한 목적단백질의 생산방법
ES2345335T3 (es) 2003-02-01 2010-09-21 Millipore Corporation Elementos geneticos mejorados que proporcionan altos niveles de expresion.
EP1676911B1 (de) * 2003-10-24 2010-04-21 Juridical Foundation, The Chemo-Sero-Therapeutic Research Institute Neue rekombinante tierzellen mit hoher proteinproduktion, verfahren zur konstruktion davon sowie verfahren zur massenproduktion von protein unter verwendung davon
ATE546531T1 (de) * 2003-12-31 2012-03-15 Kalobios Inc Transaktivierungssystem für säugerzellen
WO2007015691A2 (en) * 2004-07-23 2007-02-08 Immunomedics, Inc. Methods and compositions for increasing longevity and protein yield from a cell culture
US7531327B2 (en) * 2004-07-23 2009-05-12 Immunomedics, Inc. Methods and compositions for increasing longevity and protein yield from a cell culture
US7537930B2 (en) 2004-07-23 2009-05-26 Immunomedics, Inc. Mammalian cell lines for increasing longevity and protein yield from a cell culture
AU2005333513B2 (en) * 2004-07-23 2011-06-02 Immunomedics, Inc. Methods and compositions for increasing longevity and protein yield from a cell culture
US7608425B2 (en) * 2004-07-23 2009-10-27 Immunomedics, Inc. Methods for protein expression in mammalian cells in serum-free medium
GB0509965D0 (en) 2005-05-17 2005-06-22 Ml Lab Plc Improved expression elements
EP2011880B1 (de) * 2006-04-13 2012-10-24 Chugai Seiyaku Kabushiki Kaisha Taurintransporter-gen
JP2009535019A (ja) * 2006-04-21 2009-10-01 バイエル・ヘルスケア・エルエルシー 灌流培養への哺乳動物細胞中の抗アポトーシス遺伝子の応用
EP2118270A2 (de) * 2007-01-08 2009-11-18 Millipore Corporation Zellkulturverfahren für die produktion rekombinanter proteine bei verminderter konzentration von einem oder mehreren kontaminanten
EP2300600B1 (de) * 2008-06-13 2015-09-30 Janssen Biotech, Inc. Verfahren zur verbesserung von lebensfähigkeit und produktivität bei der zellkultur
US20130065312A1 (en) * 2009-11-03 2013-03-14 The Johns Hopkins University Method and composition for generating programmed cell death resistant algal cells
HUP1000243A2 (en) 2010-05-06 2012-01-30 Avidin Kft 8-hidroxy-quinoline derivatives
KR102711314B1 (ko) 2018-06-28 2024-09-27 삼성디스플레이 주식회사 유기 발광 표시 장치

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136310A (en) * 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
DE669986T1 (de) * 1992-11-13 1996-10-10 Idec Pharma Corp Völlig unfunktionelle konsensus-kozak-sequenzen zur säugetier-exprimierung.
US5565491A (en) * 1994-01-31 1996-10-15 Bristol-Myers Squibb Company Use of phosphotyrosine phospatase inhibitors for controlling cellular proliferation
US5550050A (en) * 1994-04-15 1996-08-27 Cytotherapeutics, Inc. Method for implanting encapsulated cells in a host
US5811524A (en) * 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
US6001358A (en) * 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US6087129A (en) * 1996-01-19 2000-07-11 Betagene, Inc. Recombinant expression of proteins from secretory cell lines
US5897992A (en) * 1996-09-27 1999-04-27 Cold Spring Harbor Laboratory Cell-free assay using oncogene-induced apoptosis in drug-resistant cells
US6011138A (en) * 1997-02-20 2000-01-04 Idec Pharmaceuticals Corporation Gamma-1 anti-human CD23 monoclonal antibodies
US5969102A (en) * 1997-03-03 1999-10-19 St. Jude Children's Research Hospital Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
US5830698A (en) * 1997-03-14 1998-11-03 Idec Pharmaceuticals Corporation Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
WO2000008057A2 (en) * 1998-08-07 2000-02-17 Immunex Corporation Molecules designated b7l-1
US6570002B1 (en) * 1999-02-26 2003-05-27 The Johns Hopkins University Inhibitor of programmed cell death
US6140118A (en) * 1999-08-11 2000-10-31 Wisconsin Alumni Research Foundation Avian blastodermal cell lines
CA2384880C (en) * 1999-09-27 2010-09-21 Genentech, Inc. Methods for making recombinant proteins using apoptosis inhibitors
NZ518718A (en) * 1999-11-12 2004-03-26 Merck & Co Inc Diaryl piperidyl pyrrole derivatives as antiprotozoal agents, treatment or prophylaxis of coccidiosis
KR100454016B1 (ko) 2002-01-05 2004-10-26 한국과학기술원 항예정사 유전자로 형질전환되고 ｄｈｆｒ 유전자가결핍된 신규한 ｃｈｏ 세포주, 그의 제조 방법 및 상기형질전환된 ｃｈｏ 숙주 세포를 이용한 목적단백질의 생산방법
EP1348758A1 (de) 2002-03-28 2003-10-01 Boehringer Ingelheim Pharma GmbH & Co.KG Wirtszellen mit verbessertem Überleben und Verfahren zur Herstellung von diesen Zellen

Also Published As

Publication number Publication date
ZA200400137B (en) 2006-06-28
EP1414948B1 (de) 2009-09-16
WO2003006607A9 (en) 2003-04-10
WO2003006607A3 (en) 2003-07-31
MXPA04000281A (es) 2004-07-23
EP1414948A4 (de) 2006-06-21
ZA200508985B (en) 2006-07-26
WO2003006607A2 (en) 2003-01-23
DE60233738D1 (de) 2009-10-29
ATE443131T1 (de) 2009-10-15
EP1414948A2 (de) 2004-05-06
KR20040044433A (ko) 2004-05-28
CN1526011A (zh) 2004-09-01
JP4435563B2 (ja) 2010-03-17
CA2452005C (en) 2011-03-15
US20030064510A1 (en) 2003-04-03
AU2002315534B2 (en) 2008-05-22
JP2009118851A (ja) 2009-06-04
US7604989B2 (en) 2009-10-20
CA2452005A1 (en) 2003-01-23
JP2005525782A (ja) 2005-09-02

Similar Documents

Publication Publication Date Title
NO20040101L (no) Hemming av apoptoseprosessen og forbedring av cellenes yteevne
Tang et al. Oxidative stress-modulating drugs have preferential anticancer effects-involving the regulation of apoptosis, DNA damage, endoplasmic reticulum stress, autophagy, metabolism, and migration
Hou et al. Antioxidant activities of dioscorin, the storage protein of yam (Dioscorea batatas Decne) tuber
Jacob-Ferreira et al. Activation of intracellular matrix metalloproteinase-2 by reactive oxygen–nitrogen species: Consequences and therapeutic strategies in the heart
BR9814817A (pt) Inibidores de apoptose de dipeptìdio e o uso dos mesmos
WO1999053958A3 (en) Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with prostaglandin inhibitor
WO2004043481A3 (en) Compositions containing peptide copper complexes and metalloproteinase inhibitors, and methods related thereto
ATE319465T1 (de) Therapeutische verwendung von extrakten aus sophora flavescens oder sophora subprostrata
DK472184A (da) 2-amino-5-hydroxy-4-methylpyrimidin-derivater og farmeceutiske praeparater indeholdende disse
MXPA00010070A (es) Mejora de respuestas inmunes medidas de proteina de fusion anticuerpo-citoquina por co-administracion con inhibidor de angiogenesis.
NO20013241D0 (no) Celleadhesjonsinhiberende anti-inflammatoriske og immunundertrykkende forbindelser
ATE333882T1 (de) Zusammensetzungen zur hemmung der angiogenese
DE60002484D1 (de) Zusammensetzung die einen alpha-amylase inhibitor und mindestens eine physiologisch akzeptabele komponente, der die intestinale absorption von "fast sugars" reduzieren kann, enthält
DE602004004121D1 (de) Olivenpulver
CA2037248A1 (en) Process for the production of dried pasta
Al-Malki Inhibition of α‐Glucosidase by Thiosulfinate as a Target for Glucose Modulation in Diabetic Rats
WO2004012660A3 (en) Mk2 interacting proteins
AU4300400A (en) Cereal product
MX2007005348A (es) Formas amorfas y polimorficas de sodio de telmisartan.
TR200201182T2 (tr) Kanser ve diğer hastalıkların tedavisine yönelik klorit çözeltileri
DK671188D0 (da) Acylderivater af 5-hydroxypyrimidin-forbindelser og farmaceutiske praeparater til behandling af pulmonaere, astmatiske, allergiske eller inflammatoriske tilstande
Katunuma Roles of Tryptases and Trypstatin in IgE Mediated Allergic Inflammation and AIDS-virus Infection.
Santos et al. Haemonchus contortus protease inhibition by n-alkyl ferulates from Maprounea guianensis
Bourenane et al. Incidence, timing, predictors, and impact of sustained ventricular arrythmias complicating ST-segment elevation myocardial infarction
Figueroa-Alegria et al. Use of pyrogallol red to assess carbonate anion radical formation from the bicarbonate-dependent peroxidase activity of superoxide dismutase 1

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application